COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS AS ADJUNCTIVE THERAPY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

被引：1
|
作者：
Taneja, C. [1 ]
Oster, G. [1 ]
Jing, Y. [2 ]
Baker, R. A. [2 ]
Forbes, R. A. [3 ]
Papakostas, G., I [4 ]
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] Bristol Myers Squibb Co, Plainsboro, NJ USA
[3] Otsuka Pharmaceut Dev & Commercializat, Princeton, NJ USA
[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72544-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A113 / A113
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Adjunctive Therapy with Atypical Antipsychotics for Acute Treatment of Major Depressive Disorder
    Taneja, Charu
    Papakostas, George I.
    Jing, Yonghua
    Baker, Ross A.
    Forbes, Robert A.
    Oster, Gerry
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (05) : 642 - 649
  • [2] Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder
    Yan, Tingjian
    Greene, Mallik
    Chang, Eunice
    Houle, Christy R.
    Tarbox, Marian H.
    Broder, Michael S.
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 81 - 89
  • [3] Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder
    Sussman, Matthew
    Yu, Jeffrey
    Kamat, Siddhesh A.
    Hartry, Ann
    Legacy, Susan
    Duffy, Ruth
    Aigbogun, Myrlene Sanon
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2017, 207 : 54 - 62
  • [4] Economic Outcomes with Adjunctive Cariprazine and Other Atypical Antipsychotics in Patients with Major Depressive Disorder
    Clayton, Anita H.
    Yee, Tracy
    Mercer, Daniel
    Sun, Haiyan
    Cummings, Nicholas
    Hayes, Oscar
    Parikh, Mousam
    [J]. CNS SPECTRUMS, 2023, 28 (02) : 250 - 250
  • [5] HEALTHCARE RESOURCE UTILIZATION WITH ADJUNCTIVE CARIPRAZINE AND OTHER ATYPICAL ANTIPSYCHOTICS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
    Clayton, A. H.
    Yee, T.
    Sun, H.
    Cummings, N.
    Hayes, O. A.
    Nabulsi, N.
    Parikh, M.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S104 - S104
  • [6] CHANGE IN HEALTHCARE UTILIZATION AND COSTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) INITIATING ADJUNCTIVE THERAPY WITH SECOND-GENERATION ANTIPSYCHOTICS (SGAS)
    Hagiwara, M.
    Sun, S. X.
    Moynahan, A.
    Bornheimer, R.
    Oster, G.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A119 - A119
  • [7] REDUCTION IN HOSPITALIZATIONS AND MEDICAL COST SAVINGS ASSOCIATED WITH EARLY USE OF ADJUNCTIVE ATYPICAL ANTIPSYCHOTICS IN MAJOR DEPRESSIVE DISORDER
    Seetasith, A.
    Greene, M.
    Hartry, A.
    Burudpakdee, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S186 - S186
  • [8] MOOD STABILIZERS AND ATYPICAL ANTIPSYCHOTICS IN MAINTENANCE THERAPY FOR BIPOLAR DISORDER: A COST-EFFECTIVENESS ANALYSIS
    Zimmermann, I. R.
    Kiyomoto, H. D.
    Alexandre, R. F.
    Nobre, M. R. C.
    Diaz, M. D. M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A548 - A548
  • [9] ADJUNCTIVE ATYPICAL ANTIPSYCHOTIC (AAP) CHOICE AFFECTS HEALTHCARE UTILIZATION IN MAJOR DEPRESSIVE DISORDER (MDD)
    Broder, M. S.
    Greene, M.
    Yan, T.
    Chang, E.
    Hartry, A.
    Yermilov, I
    Duffy, R.
    [J]. VALUE IN HEALTH, 2018, 21 : S78 - S79
  • [10] AN ASSESSEMENT OF THE COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS MULTIPLE COMPARATORS AS FIRST LINE ANTIDEPRESSANT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) IN BELGIUM
    Druais, S.
    Gauthier, A.
    Demyttenaere, K.
    Brignone, M.
    De Pauw, A.
    Defraigne, G.
    Annemans, L.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A338 - A338
12345